Search Result

Results for "

Mlkl-/- NIH-3T3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Akt (6) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (9) Autophagy (13) Bcr-Abl (1) BCRP (1) Biochemical Assay Reagents (1) c-Kit (5) c-Met/HGFR (5) CDK (2) DNA-PK (1) DNA/RNA Synthesis (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (6) Endogenous Metabolite (1) Epigenetic Reader Domain (1) ERK (2) Eukaryotic Initiation Factor (eIF) (2) Farnesyl Transferase (2) FGFR (5) Fungal (1) Gli (1) Hedgehog (1) Ligands for Target Protein for PROTAC (1) LPL Receptor (1) Mixed Lineage Kinase (24) Na+/Ca2+ Exchanger (1) Na+/K+ ATPase (1) Necroptosis (10) NF-κB (1) NO Synthase (1) p38 MAPK (4) PARP (1) PDGFR (5) PI3K (1) PROTACs (2) Protein Prenyltransferase (1) Raf (6) Ras (4) RET (5) RIP kinase (12) ROS Kinase (1) Ser/Thr Protease (1) Small Interfering RNA (siRNA) (3) Smo (1) STAT (3) TGF-β Receptor (2) Tie (5) Topoisomerase (2) Trk Receptor (1) VEGFR (8)
By Research Areas:	Cancer (49) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (13) Metabolic Disease (2) Neurological Disease (5)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-124429

FQI1	ERK	Cancer
FQI1 is a Late SV40 Factor (LSF) inhibitor. FQI1 inhibits cell proliferation, with IC₅₀s of 3, 0.79, 6.3 μM for NIH/3T3, HeLa, A549 cells. FQI1 can be used for cancer research .

HY-24504

MBA-m1	Mixed Lineage Kinase	Inflammation/Immunology Cancer
MBA-m1 is a *MLKL* inhibitor. MBA-m1 inhibits necroptosis in Mlkl ^−/− NIH-3T3 cells. MBA-m1 ameliorates disease in MLKL-induced dermatitis and abdominal aortic aneurysm mouse model .

HY-161921

Antifungal agent 108	Fungal	Infection
Antifungal agent 108 (compound 14d), an original imidazo[1,2-b]pyridazine derivative, shows potent antifungal activity against Madurella mycetomatis (MM55 strain) with an IC₅₀ of 0.9 μM. Antifungal agent 108 exhibits an IC₅₀ of 14.3 μM on cell viability of NIH-3T3 murine fibroblast .

HY-115562

Dorrigocin A	Ras	Inflammation/Immunology Cancer
Dorrigocin A is an analog of Migrastatin (HY-121452). Dorrigocin A can inhibit the carboxymethyltransferase involved in Ras processing and reverse the morphology of ras-transformed NIH/3T3 cells. Dorrigocin A is promising for research of anti-cancer and anti-arthritis agents .

HY-171038

STAT3-IN-39	STAT	Inflammation/Immunology
STAT3-IN-39 (compound 10K) is an orally active STAT3 inhibitor that exhibits excellent inhibitory activity against STAT3 phosphorylation, with an IC₅₀ of 0.47 μM in NIH-3T3 cells. STAT3-IN-39 inhibits the TGF-β1-induced fibrotic response and blocks the epithelial-mesenchymal transition in A549. STAT3-IN-39 can be utilized in research related to idiopathic pulmonary fibrosis .

HY-129769

CMLD012073	Eukaryotic Initiation Factor (eIF)	Cancer
CMLD012073 is an amidino-rocaglates and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012073 inhibits the growth of NIH/3T3 cells with an IC₅₀ of 10 nM. CMLD012073 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A) .

HY-N14767

Naphthablin	DNA/RNA Synthesis Bcr-Abl	Cancer
Naphthablin is a naphthoquinone compound that inhibits Abl oncogene functions. Naphthablin inhibits Abl-induced morphological transformation in v-ablts-NIH3T3 cells and inhibits RNA synthesis .

HY-129767

CMLD012612	Eukaryotic Initiation Factor (eIF)	Cancer
CMLD012612 is an amidino-rocaglate containing a hydroxamate group and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012612 inhibits cell translation and is cytotoxic to NIH/3T3 cells with an IC₅₀ value of 2 nM. CMLD012612 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A) and possesses potent anti-neoplastic activity .

HY-128041

alpha-Hydroxy farnesyl phosphonic acid Hydroxyfarnesyl phosphate	Farnesyl Transferase	Others
α-hydroxy Farnesyl phosphonic acid is a nonhydrolyzable analog of farnesyl pyrophosphate which acts as a competitive inhibitor of farnesyl transferase (FTase). At concentrations greater than 1 μM, α-hydroxy farnesyl phosphonic acid inhibits the processing of Ras in Ha-ras-transformed NIH3T3 cells.

HY-139878

MLKL-IN-1	Mixed Lineage Kinase	Inflammation/Immunology
MLKL-IN-1 is a covalent *MLKL* inhibitor with a K_D of 50 μM.

HY-148767

MLKL-IN-5	Mixed Lineage Kinase	Others
MLKL-IN-5 is a potent *MLKL* inhibitor that mediates necroptosis .

HY-156119

MLKL-IN-6	Mixed Lineage Kinase Necroptosis	Metabolic Disease Cancer
MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor targeting Mixed Lineage Kinase domain-like (MLKL). MLKL-IN-6 inhibits cell necrosis. MLKL-IN-6 inhibits MLKL phosphorylation and oligomerization during cell necrosis, inhibits immune cell death, and reduces the expression of adhesion factors. MLKL-IN-6 has low cytotoxicity, and it inhibits hepatic stellate cell activation, reduces liver fibrosis marker levels, and has anti-fibrotic effects .

HY-151542

MLKL-IN-4	Mixed Lineage Kinase Necroptosis RIP kinase	Neurological Disease
MLKL-IN-4 (compound 56) is a potent *MLKL* (Mixed lineage kinase domain-like protein) inhibitor. MLKL-IN-4 inhibits necroptosis in HT-29 cells and acts downstream of MLKL phosphorylation, with EC₅₀ of 82 nM . MLKL-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-151541

MLKL-IN-3	Mixed Lineage Kinase Necroptosis	Neurological Disease
MLKL-IN-3 (compound 66) is a potent *MLKL* (Mixed lineage kinase domain-like protein) inhibitor. MLKL-IN-3 inhibits necroptosis in HT-29 cells and acts downstream of MLKL phosphorylation, with EC₅₀ of 31 nM . MLKL-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-141889

MLKL-IN-2	Mixed Lineage Kinase	Inflammation/Immunology
MLKL-IN-2 is a *MLKL* inhibitor extracted from patent WO2021224505A1, compound (i) .

HY-146780

TGFβRI-IN-4	TGF-β Receptor	Cancer
TGFβRI-IN-4 is a highly potent and orally active TGFβ receptor type I (TGFβRI) inhibitor, with IC₅₀s of 44 nM and 42.5 nM for ALK5 and NIH3T3. TGFβRI-IN-4 can suppress tumor growth and tumor weight in tumor xenograft model .

HY-156591

*PROTAC MLKL* Degrader-1**	PROTACs Mixed Lineage Kinase	Others
PROTAC MLKL Degrader-1 (Compound 36) is a PROTAC degrader of *MLKL, with a D_max* ＞90%. PROTAC MLKL Degrader-1 contains modified CRBN ligands, linker and Lenalidomide (HY-A0003)-linker fragments. PROTAC MLKL Degrader-1 abrogates cell death in a TSZ model of necroptosis.

HY-161361

MLKL-IN-7	Mixed Lineage Kinase	Cancer
MLKL-IN-7 (compound 9) is a *MLKL* inhibitor, and shows anti-necroptosis activity in HT-29 cells with the IC₅₀ of 148.4 nM .

HY-162342

Topoisomerase I inhibitor 14	Topoisomerase	Cancer
Topoisomerase I inhibitor 14 (Compound 4h) is an inhibitor for Topoisomerase I. Topoisomerase I inhibitor 14 inhibits proliferation of A549 and C6 with IC₅₀s of 4.56 μM and 13.17 μM, without significant toxicity in healthy cells NIH3T3 (IC₅₀ is 74.44 μM), which exhibits anticancer potency .

HY-161247

5-HT2A antagonist 2	5-HT Receptor	Metabolic Disease
5HT2A antagonist 2 is an orally active, selective antagonist for 5HT_2A with IC₅₀ of 14 nM. 5-HT2A antagonist 2 exhibits good chemical, hepatocyte, and plasma stability, without significant cytotoxicity in cell lines VERO, HFL-1, L929, NIH3T3, CHO-K1 .

HY-12316R

20(S)-Hydroxycholesterol (Standard) 2 Publications Verification 20α-Hydroxycholesterol (Standard)	Smo Endogenous Metabolite	Cancer
20(S)-Hydroxycholesterol (Standard) is the analytical standard of 20(S)-Hydroxycholesterol. This product is intended for research and analytical applications. 20(S)-hydroxyCholesterol (20α-Hydroxycholesterol) is an allosteric activator of the oncoprotein smoothened (Smo) that activates the hedgehog (Hh) signaling pathway with an EC₅₀ of 3 μM in a gene transcription reporter assay using NIH3T3 cells .

HY-144828

*RIP1/RIP3/MLKL* activator 1** 3 Publications Verification	RIP kinase Mixed Lineage Kinase Necroptosis	Cancer
RIP1/RIP3/MLKL activator 1 (Compound 6i) is a potent anti-glioma agent. RIP1/RIP3/MLKL activator 1 induces necroptosis through *RIP1/RIP3/MLKL* pathway. RIP1/RIP3/MLKL activator 1 exerts acceptable BBB permeability .

HY-169072

*PROTAC MLKL* Degrader-2**	PROTACs Mixed Lineage Kinase	Cancer
PROTAC MLKL Degrader-2 (compound MP-1) is a PROTAC targeting *MLKL* (Mixed Lineage Kinase). PROTAC *MLKL* Degrader-2 is composed of PROTAC target protein ligand PROTAC *MLKL* Degrader-2 (HY-169072) (red part), E3 ligase ligand Thalidomide (HY-14658) (blue part) and PROTAC Linker N-Methylpiperazine (HY-78871) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is Thalidomide-N-methylpiperazine (HY-169074) ^{[1] ^.}

HY-162424

*ZBP1/RIP3/MLKL* activator 1**	RIP kinase Mixed Lineage Kinase Necroptosis	Cancer
ZBP1/RIP3/MLKL activator 1 (compound 3a) is a synthetically derived quinoline compound. ZBP1/RIP3/MLKL Activator 1 induces DNA damage, enhances intracellular levels of reactive oxygen species (ROS), and triggers apoptosis via the caspase pathway. Furthermore, when apoptosis is inhibited, ZBP1/RIP3/MLKL Activator 1 promotes necroptotic cell death through the ZBP1-RIP3-MLKL pathway. ZBP1/RIP3/MLKL Activator 1 is utilized in oncological research, particularly in the selective targeting of cells with impaired apoptotic function .

HY-RS22995

Mlkl Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Mlkl Rat Pre-designed siRNA Set A contains three designed siRNAs for Mlkl gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mlkl Rat Pre-designed siRNA Set A Mlkl Rat Pre-designed siRNA Set A

HY-RS08492

MLKL Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MLKL Human Pre-designed siRNA Set A contains three designed siRNAs for MLKL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MLKL Human Pre-designed siRNA Set A MLKL Human Pre-designed siRNA Set A

HY-RS16563

Mlkl Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Mlkl Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mlkl gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mlkl Mouse Pre-designed siRNA Set A Mlkl Mouse Pre-designed siRNA Set A

HY-144437

ALK5-IN-9	TGF-β Receptor	Cancer
ALK5-IN-9 (Compound 8h) is a potent and orally active inhibitor of TGFβRI (ALK5). ALK5-IN-9 inhibits ALK5 autophosphorylation and NIH3T3 cell activity with IC₅₀ values of 25 nM and 74.6 nM, respectively. ALK5-IN-9 also shows favorable pharmacokinetic profile and ameliorated hERG inhibition. ALK5-IN-9 has the potential for the research of cancer disease .

HY-117935

GGTI-286 hydrochloride	Ras	Cancer
GGTI-286 hydrochloride, a potent GGTase I inhibitor, is 25-fold more potent (IC₅₀=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 hydrochloride selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC₅₀s =2 and >30 μM, respectively). GGTI-286 hydrochloride also potently inhibits oncogenic K-Ras4B stimulation with an IC₅₀ of 1 μM .

HY-115489

GGTI-286	Ras	Cancer
GGTI-286, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC₅₀=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC₅₀s=2 and >30 μM, respectively). GGTI-286 also potently inhibits oncogenic K-Ras4B stimulation with an IC₅₀ of 1 μM .

HY-169864

KRO-105714	LPL Receptor	Inflammation/Immunology
KRO-105714 is the antagonist for sphingosine phosphocholine receptor (SPC Receptor) and sphingosine-1-phosphate receptor 1 (S1P1 Receptor) (IC₅₀=79.2 nM). KRO-105714 inhibits SPC-induced proliferation of NIH3T3 (IC₅₀=5.6 nM), inhibits SPC-induced cell migration (IC₅₀=0.59 μM) and tube formation in HUVECs. KRO-105714 inhibits SPC-induced generation of IL-4 and IL-5, exhibits anti-inflammtory efficacy in mouse atopic dermatitis models .

HY-115489A

GGTI-286 TFA	Protein Prenyltransferase	Cancer
GGTI-286 TFA, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC₅₀=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 TFA selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC₅₀s=2 and >30 μM, respectively). GGTI-286 TFA also potently inhibits oncogenic K-Ras4B stimulation with an IC₅₀ of 1 μM .

HY-137191

CH7233163	EGFR	Cancer
CH7233163 is a noncovalent ATP-competitive inhibitor for EGFR-Del19/T790M/C797S. CH7233163 can overcome Osimertinib (HY-15772)-Resistant EGFR-Del19/T790M/C797S mutation. CH7233163 blocks the EGFR phosphorylation in the Del19/T790M/C797S_NIH3T3 cells. CH7233163 has antitumor activities .

HY-117807

A-176120	Ras Farnesyl Transferase VEGFR	Cancer
A-176120 is a selective inhibitor of farnesyl transferase (IC₅₀=1.2 nM) based on a farnesyl pyrophosphate (FPP) analog, with superior selectivity against GGTaseI (IC₅₀=423 nM), GGTaseII (IC₅₀=3000 nM), and SSase (IC₅₀>10 μM). A-176120 inhibits ras processing in H-ras transformed NIH3T3 cells and HCT116 K-ras mutant cells (ED₅₀=1.6 and 0.5 μM, respectively). A-176120 has antiangiogenic and antitumor activities in vivo and reduces capillary structure formation and VEGF secretion .

HY-103086

INU-152	Raf Autophagy Apoptosis	Cancer
INU-152 is a potent and selective B-Raf inhibitor. INU-152 reduces tumor cell proliferation, enhances autophagy, and induces apoptosis by inhibiting B-Raf activity. INU-152 exhibits significant cytotoxicity against cancer cells transformed with v-Ha-ras (Ras-NIH 3T3). INU-152 can be utilized in cancer research .

HY-100573

Necrosulfonamide Maximum Cited Publications 93 Publications Verification	Mixed Lineage Kinase	Cancer
Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein *(MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL* is a critical substrate of RIP3 during the induction of necrosis .

HY-112292A

GW806742X hydrochloride 10+ Cited Publications	Mixed Lineage Kinase VEGFR	Cancer
GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a K_d of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC₅₀=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis .

HY-112292

GW806742X 10+ Cited Publications	Mixed Lineage Kinase VEGFR	Others
GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a K_d of 9.3 μM. GW806742X has activity against VEGFR2 (IC₅₀=2 nM). GW806742X retards MLKL membrane translocation and inhibits necroptosis .

HY-100573S

Necrosulfonamide-d4	Mixed Lineage Kinase	Cancer
Necrosulfonamide-d₄ is the deuterium labeled Necrosulfonamide. Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during the induction of necrosis .

HY-100573A

(E/Z)-Necrosulfonamide	Mixed Lineage Kinase	Cancer
(E/Z)-Necrosulfonamide is a racemic compound of Necrosulfonamide (HY-100573). Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein *(MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL* is a critical substrate of RIP3 during the induction of necrosis .

HY-P10811

Na2+ - Ca2+ Exchanger inhibitory peptide XIP	Na+/Ca2+ Exchanger	Neurological Disease
Na ⁺-Ca ²⁺ Exchanger inhibitory peptide (XIP) is a Na ⁺-Ca ²⁺ exchanger inhibitor with a K_i of 200 nM. Na ⁺-Ca ²⁺ Exchanger inhibitory peptide inhibits the Na ⁺-dependent Ca ²⁺ uptake and the Na ⁺-dependent Ca ²⁺ efflux of sarcolemmal vesicles in a noncompetitive manner .

HY-W408607

N-Benzylacetamidine hydrobromide	NO Synthase	Inflammation/Immunology
N-Benzylacetamidine (hydrobromide) is a acetamidine compound. N-Benzylacetamidine (hydrobromide) is a selective inducible nitric oxide synthase (iNOS) inhibitor with an IC₅₀ of 0.20 μM .

HY-169074

Thalidomide-N-methylpiperazine	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-N-methylpiperazine is an E3 Ligase Ligand-Linker Conjugate. Thalidomide-N-methylpiperazine can be used to synthesize PROTAC MLKL Degrader-2 (HY-169072) to exhibit antinecroptotic activity on human cell lines and effectively degrade *MLKL* in the HT-29 xenograft mouse model .

HY-101524

TC13172 2 Publications Verification	Mixed Lineage Kinase	Cancer
TC13172 is a mixed lineage kinase domain-like protein (MLKL) inhibitor with an EC₅₀ value of 2 nM for HT-29 cells .

HY-149393

RIPK3-IN-3	Mixed Lineage Kinase RIP kinase	Cancer
RIPK3-IN-3 (compound 20) is a selective inhibitor of RIP kinase RIPK3 (IC₅₀=10 nM). RIPK3 mediates the phosphorylation of Mixed Lineage Kinase (MLKL) and causes necroptosis, while RIPK3-IN-3 inhibits p-MLKL oligomerization and thereby inhibits necroptosis. RIPK3-IN-3 also downregulates CXCL5 secretion and inhibits AsPC-1 cell migration and invasion .

HY-133023

Indium(III) isopropoxide	Biochemical Assay Reagents	Others
Indium(III) Isopropoxide is an organo-metallic compound. Indium(III) Isopropoxide uesd as a hydrogen transfer catalyst for conversion of benzylic alcohols into aldehydes or ketones via Oppenauer oxidation. Indium(III) Isopropoxide also can be used as metal precursor .

HY-157039

RIPK1-IN-17	RIP kinase	Inflammation/Immunology
RIPK1/3-IN-17 (Compound 10) is a RIPK1 and RIPK3 inhibitor. RIPK1/3-IN-17 specifically inhibits necroptosis by inhibiting RIPK1, RIPK3, and MLKL phosphorylation .

HY-152472

ENT-C225	Trk Receptor	Neurological Disease
ENT-C225 is an effective activator of TrkB neurotrophin receptor. ENT-C225 has high effect on activating TrkB receptor (TrkBR), and has good physicochemical properties and neuroprotective properties .

HY-169073

TC13172-NH-COOH	Ligands for Target Protein for PROTAC	Others
TC13172-NH-COOH is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). TC13172-NH-COOH can be used for synthesis PROTAC MLKL Degrader-2 (HY-169072) .

HY-N2909

Aurantiamide	NF-κB RIP kinase Mixed Lineage Kinase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as *RIPK3/MLKL* signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models .

Cat. No.	Product Name	Target	Research Area

HY-P10811

Na2+ - Ca2+ Exchanger inhibitory peptide XIP	Na+/Ca2+ Exchanger	Neurological Disease
Na ⁺-Ca ²⁺ Exchanger inhibitory peptide (XIP) is a Na ⁺-Ca ²⁺ exchanger inhibitor with a K_i of 200 nM. Na ⁺-Ca ²⁺ Exchanger inhibitory peptide inhibits the Na ⁺-dependent Ca ²⁺ uptake and the Na ⁺-dependent Ca ²⁺ efflux of sarcolemmal vesicles in a noncompetitive manner .

Cat. No.	Product Name

HY-K2014

PEI Transfection Reagent 10+ Cited Publications
MCE PEI Transfection Reagent is designed based on 25 kDa PEI. It has high-efficiency, low-toxicity, strong-stability, and is suitable for many cell types, such as HEK-293、HEK-293T、CHO-K1、COS-1、COS-7、NIH/3T3、Sf9、HepG2 and HeLa et, even some hard-to-transfect cells. It can also be applied to large-scale recombinant protein expression and virus production.

Cat. No.	Product Name	Target	Research Area

HY-P991226

RG7287	Inhibitory Antibodies	Cancer
RG7287 is an activating antibody inhibitor targeting human CDCP1. RG7287 prevents the loss of contact inhibition caused by the co-transformation of NIH3T3 cells with CDCP1 and Src in focus formation assays. RG7287 inhibits tumor cell proliferation and leads to a significant reduction in CDCP1 levels .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-12316R

20(S)-Hydroxycholesterol (Standard) 2 Publications Verification 20α-Hydroxycholesterol (Standard)	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Steroids Cancer	Smo Endogenous Metabolite
20(S)-Hydroxycholesterol (Standard) is the analytical standard of 20(S)-Hydroxycholesterol. This product is intended for research and analytical applications. 20(S)-hydroxyCholesterol (20α-Hydroxycholesterol) is an allosteric activator of the oncoprotein smoothened (Smo) that activates the hedgehog (Hh) signaling pathway with an EC₅₀ of 3 μM in a gene transcription reporter assay using NIH3T3 cells .

HY-N2909

Aurantiamide	Alkaloids Structural Classification Classification of Application Fields Other Alkaloids Source classification Umbelliferae Plants Inflammation/Immunology Disease Research Fields Carphephorus corymbosus (Nutt.) Torr. & A.Gray	NF-κB RIP kinase Mixed Lineage Kinase
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as *RIPK3/MLKL* signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models .

HY-N14767

Naphthablin	Structural Classification Natural Products Microorganisms Source classification	DNA/RNA Synthesis Bcr-Abl
Naphthablin is a naphthoquinone compound that inhibits Abl oncogene functions. Naphthablin inhibits Abl-induced morphological transformation in v-ablts-NIH3T3 cells and inhibits RNA synthesis .

HY-N8380

(-)-Latifolin	Structural Classification Dalbergia hupeana Hance Source classification Phenols Polyphenols Plants Fabaceae	Apoptosis Autophagy PI3K Necroptosis
(-)-Latifolin, a flavonoid, induces apoptotic cell death by targeting PI3K/AKT/mTOR/p70S6K signaling. (-)-Latifolin significantly inhibits the cell proliferation of oral squamous cell carcinoma (OSCC), and causes the anti-metastatic activities by effectively blocking cell migration, invasion, and adhesion via the inactivation of FAK/Src. (-)-Latifolin suppresses autophagic-related proteins and autophagosome formation. (-)-Latifolin inhibits necroptosis by dephosphorylating necroptosis-regulatory proteins (RIP1, RIP3, and MLKL). (-)-Latifolin has beneficial effects on anti-aging, anti-carcinogenic, anti-inflammatory, and cardio-protective activities .

HY-N3007A

(E)-Naringenin chalcone	Structural Classification Phenols Polyphenols Solanum lycopersicum L. Solanaceae Plants	Others
(E)-Naringenin chalcone is an orally active anti-allergic agent. (E)-Naringenin chalcone also has antioxidant, anti-inflammatory activities. (E)-Naringenin chalcone can improve adipocyte functions. (E)-Naringenin chalcone inhibits histamine release from rat peritoneal mast cell .

Cat. No.	Compare	Product Name	Species	Source

HY-P702574

	MLKL Protein, Human (His-SUMO) 1 Publications Verification hMlkl; Mixed lineage kinase domain like	Human	E. coli
	MLKL protein is a pseudokinase that plays a key role in TNF-induced necroptosis. Despite lacking intrinsic kinase activity, it is activated through RIPK3 phosphorylation, leading to homotrimerization, plasma membrane localization, and execution of necroptosis. MLKL Protein, Human (His-SUMO) is the recombinant human-derived MLKL protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-100573S

Necrosulfonamide-d4
Necrosulfonamide-d₄ is the deuterium labeled Necrosulfonamide. Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during the induction of necrosis .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81878

	*Phospho-MLKL* (Ser358) Antibody (YA1623)** Mlkl	WB, IHC-P	Human
	Phospho-MLKL (Ser358) Antibody (YA1623) is a non-conjugated IgG antibody, targeting Phospho-MLKL (Ser358), with a predicted molecular weight of 54 kDa. Phospho-MLKL (Ser358) Antibody (YA1623) can be used for WB, IHC-P experiment in human background.

HY-P80227

	MLKL Antibody (YA289)	WB, IHC-P	Human, Mouse
	MLKL Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 54 kDa, targeting to MLKL. It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse.

HY-P80468

	*Phospho-MLKL* (Ser345) Antibody (YA174)**	WB, IHC-P	Mouse
	Phospho-MLKL (Ser345) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 54 kDa, targeting to Phospho-MLKL (S345). It can be used for WB,IHC-P assays with tag free, in the background of Mouse.